Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany lub przerzutowy rak płuca (etap IIIB/C lub IV) z mutacją genu EGFR
- •Choroba pogorszyła się mimo leczenia lekami trzeciej generacji (takimi jak osimertinib)
- •Obecność mutacji C797X w genie (wykazanej w badaniu krwi lub tkanki)
- •Co najmniej jeden widoczny guz do zmierzenia
- •Dobry stan ogólny (skala ECOG 0-1)
- •Prawidłowe wyniki badań krwi: wystarczająca liczba białych krwinek, płytek i hemoglobiny
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
Nashville, United States
Oncology Consultants (OC) - Texas Medical Center - Cancer Center
Houston, United States
Shanghai East Hospital, Tongji University
Shanghai, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Centre Léon Bérard
Lyon, France
CHU Hôpital de la Timone
Marseille, France
Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau
Saint-Herblain, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Gustave Roussy
Villejuif, France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Netherlands Cancer Institute
Amsterdam, Netherlands
Hospital Quironsalud Barcelona
Barcelona, Spain
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
Hospital San Pedro
Logroño, Spain
Hospital Universitario La Paz
Madrid, Spain
Centro Intergral Oncologico Clara Campal (CIOCC) (START Madrid)
Madrid, Spain
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Trial contact
Data Protection Officer
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.